CASR and Hypercalciuria: Gain-of-function mutations in the TM6–TM7 transmembrane region of CASR drive ADH1 by increasing receptor sensitivity to calcium, lowering the PTH suppression threshold, and causing hypocalcemia with low PTH and hypercalciuria.